Latest news with #Lonza
Saba Yemen
a day ago
- Automotive
- Saba Yemen
European Stocks Rise Amid Optimism Over Trade Deal with the U.S.
Brussels – SABA: European stocks climbed on Wednesday, led by gains in the automotive sector, as optimism grew over a potential trade agreement with the United States following Washington's recent deal with Japan. The Stoxx 600 index rose nearly 1% to 549.6 points, recovering from three consecutive sessions of losses. Meanwhile, the UK's FTSE 100 extended its winning streak to a fifth straight session, hitting a record high. Other regional indices also advanced, with France's CAC 40 leading the gains, jumping 1.3%. The auto manufacturing sector was the top performer, surging 3.4%, tracking gains in Asian competitor stocks. Shares of Porsche soared 7.6%, while Mercedes-Benz climbed 5.8%. Swiss company Lonza was among the strongest performers, rising 5.4% after surpassing profit expectations, driven by its pharmaceutical manufacturing unit. However, shares of ASM International fell 7.7%, weighing on the tech sector and marking the biggest decline on the Stoxx 600. German software giant SAP also dropped 3.5% after reporting higher Q2 profits due to cost-cutting and increased demand but refraining from raising its full-year earnings forecast. The market rally reflects growing confidence in easing trade tensions, with investors closely watching for further developments in U.S.-Europe trade negotiations. Whatsapp Telegram Email Print more of (Economy)
Reuters
2 days ago
- Business
- Reuters
Lonza tops core profit forecast driven by main drug manufacturing business
July 23 (Reuters) - Switzerland's Lonza (LONN.S), opens new tab posted 23% growth in its half-year core profit on Wednesday, beating market expectations, driven by a strong performance in its contract drug manufacturing (CDMO) business and contributions from its Vacaville site in the U.S. Lonza, which produces monoclonal antibodies used in a new class of Alzheimer's drugs, reported core earnings before interest, taxes, depreciation and amortization (EBITDA) of 1.1 billion Swiss francs ($1.39 billion). Analysts polled by Vara Research had forecast a core profit of 993 million francs. Lonza had said in December it wanted to exit its capsules and health ingredients (CHI) business, as a decline in demand for pharmaceutical supplies since the end of the COVID-19 pandemic has been weighing on the group's performance. The company is well on track with the internal preparations to carve out and exit the business, it said in Thursday's earnings statement. Lonza's finance chief Philippe Deecke said on a call with journalists that it was too early to estimate a value of a possible sale. According to analysts, such deal could be valued between 2 billion and 4 billion francs. Lonza reported half-year sales of 3.6 billion francs, slightly ahead of the consensus estimate of 3.5 billion francs. Sales in the CDMO business, which made up 86% of the group's sales, benefited from strong demand in mammalian, bioconjugates and small molecules technology platforms. Based on this, Basel-based Lonza raised its outlook for the CDMO business, expecting sales growth of 20-21% at constant exchange rates, versus close to 20% previously, and a core EBITDA margin of 30-31%, against a prior target of close to 30%. Lonza also expects its second-half sales to be higher than in the first half of the year, as its delivery pipeline is more weighted towards the latter part of the year. The pharmaceutical supplier said it assumes a negative currency exchange effect of 2.5% to 3.5% on its annual sales and core EBITDA, mainly due to the weakening U.S. dollar versus Swiss franc. Lonza makes roughly 66% of its sales in foreign currencies, of which the U.S. dollar represents the largest part. ($1 = 0.7936 Swiss francs) (This story has been refiled to correct a typo in the headline)
Reuters
2 days ago
- Business
- Reuters
Lonza's tops core profit forecast driven by main drug manufacturing business
July 23 (Reuters) - Switzerland's Lonza (LONN.S), opens new tab posted 23% growth in its half-year core profit on Wednesday, beating market expectations, driven by a strong performance in its contract drug manufacturing (CDMO) business and contributions from its Vacaville site in the U.S. Lonza, which produces monoclonal antibodies used in a new class of Alzheimer's drugs, reported core earnings before interest, taxes, depreciation and amortization (EBITDA) of 1.1 billion Swiss francs ($1.39 billion). Analysts polled by Vara Research had forecast a core profit of 993 million francs. Lonza had said in December it wanted to exit its capsules and health ingredients (CHI) business, as a decline in demand for pharmaceutical supplies since the end of the COVID-19 pandemic has been weighing on the group's performance. The company is well on track with the internal preparations to carve out and exit the business, it said in Thursday's earnings statement. Lonza's finance chief Philippe Deecke said on a call with journalists that it was too early to estimate a value of a possible sale. According to analysts, such deal could be valued between 2 billion and 4 billion francs. Lonza reported half-year sales of 3.6 billion francs, slightly ahead of the consensus estimate of 3.5 billion francs. Sales in the CDMO business, which made up 86% of the group's sales, benefited from strong demand in mammalian, bioconjugates and small molecules technology platforms. Based on this, Basel-based Lonza raised its outlook for the CDMO business, expecting sales growth of 20-21% at constant exchange rates, versus close to 20% previously, and a core EBITDA margin of 30-31%, against a prior target of close to 30%. Lonza also expects its second-half sales to be higher than in the first half of the year, as its delivery pipeline is more weighted towards the latter part of the year. The pharmaceutical supplier said it assumes a negative currency exchange effect of 2.5% to 3.5% on its annual sales and core EBITDA, mainly due to the weakening U.S. dollar versus Swiss franc. Lonza makes roughly 66% of its sales in foreign currencies, of which the U.S. dollar represents the largest part. ($1 = 0.7936 Swiss francs)
Reuters
2 days ago
- Business
- Reuters
Lonza's half-year core profit tops market expectations
July 23 (Reuters) - Swiss contract drug manufacturer Lonza (LONN.S), opens new tab reported a rise in its half-year core earnings on Wednesday, beating market expectations, aided by contributions from its Vacaville site in the U.S and strong performance in the mammalian, bioconjugates and small molecules technology platforms. Lonza reported earnings before interest, taxes, depreciation and amortization (EBITDA) of 1.1 billion Swiss francs ($1.39 billion) for the first six months of 2025, compared with 893 million francs in the same period last year. Analysts polled by Vara Research had forecast a core profit of 993 million francs. ($1 = 0.7936 Swiss francs)
San Francisco Chronicle
31-05-2025
- Climate
- San Francisco Chronicle
A river dammed by a huge Swiss landslide is flowing again. That's a relief to authorities
GENEVA (AP) — A small Alpine river dammed by a landslide that largely buried the Swiss village of Blatten is now flowing through the debris, and the level of a newly created lake that raised worries about potential new destruction has fallen, authorities said Saturday. A huge mass of rock, ice and mud from the Birch glacier thundered into the Lötschental valley in southern Switzerland on Wednesday, destroying much of the village. Buildings that weren't buried were submerged in a lake created by the small Lonza River, whose course was dammed by the mass of material. Authorities worried that water pooling above the mass of rock and ice could lead to risks of its own. Still, the regional government in Valais canton (state) said that the Lonza has been flowing through the full length of the debris since Friday. Geologist and regional official Raphaël Mayoraz said Saturday that the level of the lake has since gone down about 1 meter (3.3 feet). 'The speed at which this lake is emptying comes from the river eroding the deposit,' he said at a news conference. 'This erosion is relatively slow, but that's a good thing. If it is too fast, then there is instability in this channel, and that could lead to small slides of debris.' 'The Lonza appears to have found its way, but it too early to be able to give an all-clear,' said Matthias Bellwald, Blatten's mayor. The outlet of a dam downstream at Ferden, which is normally used to generate electricity, was opened partially on Friday evening to allow water to flow further down the valley and regulate the volume of water behind the dam. Authorities are still leaving open the possibility of evacuations further downstream if required, though the risk to other villages appears very low.
